| HOME >> MEDICINE >> TECHNOLOGY |
Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010
Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010
Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010
Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010
Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010
Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010
Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010
Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010
Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010
Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010
Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010
Table 28: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010
Table 29: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010
Figure 1: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001-2020
Figure 2: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010
Figure 3: Colorectal Cancer Therapeutics Market, France, Opportunity and Unmet Need, 2009
Figure 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010
Figure 5: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010
Figure 6: Colorectal Cancer Therapeutics Market, France, Sales Value
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |